NKTR-255 in combination with durvalumab following chemoradiation was well-tolerated in patients with non–small cell lung ...
The 22nd Annual Winter Lung Cancer Conference, January 31-February 2, 2025, will cover advances in NSCLC and SCLC treatment.
Therapeutics and collaborators at The University of Texas MD Anderson Cancer Center presented late-breaking results from a Phase ...
In a move aimed at providing relief to cancer patients, the National Pharmaceutical Pricing Authority (NPPA) has directed ...
Akeso begins patient enrollment in phase 3 trial of ivonescimab combination as first-line therapy for biliary tract tumours, compared to durvalumab: China Monday, November 4, 2024 ...
The top stories in non-small cell lung cancer (NSCLC) for 2024 included practice-changing results in EGFR-mutant disease, an ...
Govt asks manufacturers to cut price of 3 anti-cancer drugs The Indian government has instructed companies to lower the prices of anti-cancer drugs Trastuzumab, Osimertinib, and Durvalumab following ...
Osimertinib and Durvalumab – in line with the government’s commitment to ensure the availability of drugs at affordable ...
New Delhi- The government has asked the companies to reduce prices of three anti-cancer drugs to pass on the benefit of ...
The National Pharmaceutical Pricing Authority (NPPA) on Tuesday issued a memorandum directing drug manufacturers to reduce ...
While presenting the Union Budget for 2024-25 in the Lok Sabha, Finance Minister Nirmala Sitharaman proposed to cut customs duties on Trastuzumab, Osimertinib and Durvalumab from 10 per cent to nil.